S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:GALT

Galectin Therapeutics (GALT) Stock Price, News & Analysis

$2.39
-0.02 (-0.83%)
(As of 03/28/2024 ET)
Today's Range
$2.30
$2.43
50-Day Range
$1.60
$2.44
52-Week Range
$1.28
$2.48
Volume
57,667 shs
Average Volume
71,790 shs
Market Capitalization
$147.82 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.00

Galectin Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
360.3% Upside
$11.00 Price Target
Short Interest
Bearish
5.05% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.85mentions of Galectin Therapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
Acquiring Shares
$895 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.74) to ($0.66) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.36 out of 5 stars

Medical Sector

597th out of 938 stocks

Pharmaceutical Preparations Industry

267th out of 417 stocks

GALT stock logo

About Galectin Therapeutics Stock (NASDAQ:GALT)

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

GALT Stock Price History

GALT Stock News Headlines

Grab Your Free Bitcoin Today!
And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.
GALT Galectin Therapeutics Inc.
Your $200 account credit is about to expire
Update to MarketBeat All Access and Save $300 on Your Annual Subscription
Galectin Therapeutics GAAP EPS of -$0.24
Galectin Therapeutics: Q3 Earnings Insights
Galectin Therapeutics Inc. (PHPN.F)
See More Headlines
Receive GALT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Galectin Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/15/2021
Today
3/28/2024
Next Earnings (Estimated)
4/04/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:GALT
Employees
12
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$11.00
High Stock Price Target
$11.00
Low Stock Price Target
$11.00
Potential Upside/Downside
+360.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-38,780,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($0.58) per share

Miscellaneous

Free Float
29,255,000
Market Cap
$147.82 million
Optionable
Optionable
Beta
0.82
These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

  • Mr. Joel Lewis (Age 54)
    President, CEO & Director
    Comp: $870.66k
  • Mr. Jack W. Callicutt CPA (Age 57)
    CFO, Treasurer & Corporate Secretary
    Comp: $492.62k
  • Dr. Pol F. Boudes M.D. (Age 67)
    Ph.D., Chief Medical Officer
    Comp: $720.64k
  • Robert Tritt
    General Counsel
  • Mr. Jeff Katstra
    Head of CMC & Pharmaceutical Development
  • Ms. Beth Knowles
    Executive Assistant & Officer Manager

GALT Stock Analysis - Frequently Asked Questions

Should I buy or sell Galectin Therapeutics stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Galectin Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" GALT shares.
View GALT analyst ratings
or view top-rated stocks.

What is Galectin Therapeutics' stock price target for 2024?

1 Wall Street analysts have issued 12-month target prices for Galectin Therapeutics' shares. Their GALT share price targets range from $11.00 to $11.00. On average, they predict the company's stock price to reach $11.00 in the next year. This suggests a possible upside of 360.3% from the stock's current price.
View analysts price targets for GALT
or view top-rated stocks among Wall Street analysts.

How have GALT shares performed in 2024?

Galectin Therapeutics' stock was trading at $1.66 at the start of the year. Since then, GALT stock has increased by 44.0% and is now trading at $2.39.
View the best growth stocks for 2024 here
.

When is Galectin Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024.
View our GALT earnings forecast
.

How were Galectin Therapeutics' earnings last quarter?

Galectin Therapeutics Inc. (NASDAQ:GALT) announced its quarterly earnings data on Monday, November, 15th. The company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.18) by $0.04.

What ETFs hold Galectin Therapeutics' stock?

ETFs with the largest weight of Galectin Therapeutics (NASDAQ:GALT) stock in their portfolio include Horizon Kinetics Medical ETF (MEDX),

What other stocks do shareholders of Galectin Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Galectin Therapeutics investors own include Sorrento Therapeutics (SRNE), Catalyst Pharmaceuticals (CPRX), Viking Therapeutics (VKTX), Exelixis (EXEL), Progenics Pharmaceuticals (PGNX), Rigel Pharmaceuticals (RIGL), TherapeuticsMD (TXMD), Novavax (NVAX), Verastem (VSTM) and Immunomedics (IMMU).

Who are Galectin Therapeutics' major shareholders?

Galectin Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Atria Wealth Solutions Inc. (0.40%), Cambridge Investment Research Advisors Inc. (0.20%), Cutter & CO Brokerage Inc. (0.19%), Solutions 4 Wealth Ltd (0.06%), Beacon Capital Management LLC (0.04%) and Retirement Guys Formula LLC (0.03%). Insiders that own company stock include Elissa J Schwartz, Fund LP 10X, Jack W Callicutt, Joel Lewis, Kary Eldred, Kevin D Freeman and Richard A Jr Zordani.
View institutional ownership trends
.

How do I buy shares of Galectin Therapeutics?

Shares of GALT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:GALT) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners